Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huzhang Mao

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Lancet (London, England)|June 29, 2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialW Timothy Garvey, Juan P Frias, Ania M Jastreboff, et al.
The Oncologist|June 16, 2020
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic FindingsMansoor Saleh, Philippe A Cassier, Lauriane Eberst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i>-mutant Non-small Cell Lung CancerHelena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 StudyAdnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Lancet (London, England)|June 29, 2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialW Timothy Garvey, Juan P Frias, Ania M Jastreboff, et al.
The Oncologist|June 16, 2020
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic FindingsMansoor Saleh, Philippe A Cassier, Lauriane Eberst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i>-mutant Non-small Cell Lung CancerHelena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 StudyAdnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Pageof 2